Pramine
Major Depressive Disorder
Hospital de Clinicas de Porto AlegreSmall moleculePhase 4 / ApprovedDormant
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 89/ 100
Competitive context
198 Active assets in the Major Depressive Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Risperidone Johns Hopkins University | Phase 4 | BBB |
Selegiline Corium Innovations, Inc. | Phase 4 | BBB |
Edivoxetine Eli Lilly and Company | Phase 3 | BBB |
(1S,2R)-MILNACIPRAN Allergan | Phase 4 | BBB |
Brexpiprazole Nova Scotia Health Authority | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Pramine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →